科代诊断美股招股说明书(2025-12-19版)

PROSPECTUS SUPPLEMENT(To Prospectus dated April 6, 2023) Co-Diagnostics, Inc.Up to $10,000,000 Shares of Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated April 6, 2023, filed with the Securitiesand Exchange Commission as a part of our registration statement on Form S-3 (File No. 333-270628), as supplemented by theprospectus supplement dated October 20, 2025 (as supplemented, the Prior Prospectus), relating to the offer and sale of shares of ourcommon stock, $0.001 par value per share, pursuant to the Equity Distribution Agreement (“Equity Distribution Agreement”) withMaxim Group LLC (“Maxim”), dated October 20, 2025, we previously entered into with Maxim. This prospectus supplement shouldbe read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein The prospectus supplement dated October 20, 2025, indicated that we were, at that time, subject to General Instruction I.B.6. of FormS-3, which limited the amount that we were able to sell under the registration statement of which the prospectus forms a part. We arecurrently no longer subject to the offering limits imposed by General Instruction I.B.6. of Form S-3. If we become subject to the As of the date of this prospectus supplement, we have sold an aggregate of 950,000 shares for gross proceeds of $266,560 pursuant tothe Equity Distribution Agreement. As a result of such prior sales, as of the date of this prospectus supplement, shares having an Our Common Stock is listed on The Nasdaq Capital Market under the symbol “CODX.” The last reported sale price of our CommonStock on The Nasdaq Capital Market on December 18, 2025 was $0.2759 per share. Investing in the offered securities involves a high degree of risk. See “Risk Factors” beginning on page S-4 of this prospectussupplement and page 6 of the accompanying prospectus for a discussion of information that you should consider before Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any Sole Sales Agent Maxim Group LLC The date of this prospectus supplement is December 19, 2025